Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-part Phase 1/2 Open-label Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours

NCT07563738 is registered in ClinicalTrials.gov with Orion Corporation, Orion Pharma as lead sponsor.

NCT NCT07563738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07563738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-part Phase 1/2 Open-label Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours
Lead sponsor
Orion Corporation, Orion Pharma
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 27, 2026
Completion date
September 30, 2029
Enrollment
229 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma, nsclc (advanced non-small cell lung cancer), pancreatic cancer